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esponsibility of Xi'aAbstract Two selective stability-indicating HPLC methods are described for determination of
rabeprazole sodium (RZ)–mosapride citrate (MR) and RZ–itopride hydrochloride (IO) mixtures in the
presence of their ICH-stress formed degradation products. Separations were achieved on X-Bridge C18
column using two mobile phases: the ﬁrst for RZ–MR mixture consisted of acetonitrile: 0.025 M KH2PO4
solution: TEA (30:69:1 v/v; pH 7.0); the second for RZ–IO mixture was at ratio of 25:74:1 (v/v; pH 9.25).
The detection wavelength was 283 nm. The two methods were validated and validation acceptance criteria
were met in all cases. Peak purity testing using contrast angle theory, relative absorbance and log A versus
the wavelengths plots were presented. The % recoveries of the intact drugs were between 99.1% and
102.2% with RSD% values less than 1.6%. Application of the proposed HPLC methods indicated that the
methods could be adopted to follow the stability of their formulations.
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n Jiaotong University.1. Introduction
Rabeprazole sodium (RZ) is chemically designed as (7) sodium-
2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl] methylsulﬁnyl]-
1H-benzimidazole [1]. It is a proton pump inhibitor that covalently
binds and inactivates the gastric parietal cell proton pump (Hþ/Kþ
ATPase) and is used in the management of acid-related disordersvier B.V. All rights reserved.
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have been reported for the determination of RZ in pharmaceutical
dosage forms (as single component) by HPLC [3–10], stability-
indicating HPLC in the presence of its degradation products
[11,12] and TLC-densitometric determinations [9,13]. Several
analytical methods have been described for the simultaneous
determination of RZ and domperidone using HPLC method [14],
with itopride using HPLC [15–19], high-performance thin layer
chromatography (HPTLC) densitometry [20] and spectro-
photometric methods [21,22]. A through literature search reveals
that HPLC and TLC methods had been described for the
simultaneous determination of RZ and mosapride in combined
dosage form [23].
Mosapride citrate (MR) is chemically designed as 4-amino-5-
chloro-2-ethoxy-N-{[4-(4-ﬂuorobenzyl) morpholin-2-yl] methyl}
benzamide. It is a potent gastroprokinetic agent with selectivity
for 5-HT4 receptor and is used in the treatment of gastrointestinal
motility dysfunction associated with non-ulcer dyspepsia and
esophagitis [1]. Reviewing the literature in hand, the reported
HPLC method for the determination of MR as binary mixture with
RZ [23] was described.
Itopride hydrochloride (IO) is chemically designed as
N–[4-[2-(dimethylamino) ethoxy]-benzyl]-3,4-dimethoxy benza-
mide hydrochloride [1]. IO is a gastroprokinetic drug dedicated
for the treatment of patients with symptomatic functional dyspep-
sia. Literature survey revealed that HPLC [15–19], spectrophoto-
metric [21,22] and HPTLC [20] methods had been described for
the simultaneous determination of IO with RZ in combined dosage
forms and are nonstability-indicating methods. On the other hand,
the investigated drugs RZ, MR and IO are not yet ofﬁcial in any of
the pharmacopoeia.
The drug stability testing guidelines [24] require that analysis
of stability samples should be performed using validated stability-
indicating analytical methods. It also recommends carrying
out stress testing on the drug substance to elucidate its inherentFig. 1 Structural formulae ostability characteristics and hence supporting the suitability of the
proposed analytical procedures [24–26] for testing drug substance
or drug combination product. To the best of our knowledge, no
article related to the HPLC stability-indicating method for the
simultaneous determination of RZ–MR or/and RZ–IO mixtures in
pharmaceutical dosage forms has ever been mentioned in the
literature, which is the aim of this work. Thereafter, methods were
validated according to ICH guidelines [25] and USP analytical
method validation parameters [27].
Furthermore, the proposed HPLC methods were applied to
the determination of RZ in its capsule dosage forms containing
either MR or IO. Fig. 1 shows the structural formulae of the
investigated drugs.2. Experimental
2.1. Chemicals
RZ, kindly provided by Quimica Sintetica S.A. (Madrid, Spain),
IO and MR of pharmaceutical grade, purchased from Kangnin
Pharmaceutical Co. (Sanmen County, China), were certiﬁcated to
contain 99.37%, 99.30% and 99.55%, respectively. Acetonitrile
used was of HPLC grade (BDH, Poole, UK). Orthophosphoric
acid solution (85%), potassium dihydrogen phosphate and
TEA were of HPLC grade (Merck, Darmstadt, Germany). Hydro-
gen peroxide (30 volumes) was from Qualigens Fine Chemicals
(Glaxo Ltd., England). Sodium hydroxide pellets and concentrated
hydrochloric acid solution were analytical grade (Germany).
HPLC water was generated in-house using a Millipore, Milli-Q
reverse osmosis plus system (Bedford, MA, USA). Veloz-Ms
capsules labeled to contain 20 mg RZ and 15 mg MR per capsule
were manufactured by Torrents Pharmaceutical Ltd. Zorites
capsules labeled to contain 20 mg RZ and 150 mg IO per capsule
were manufactured by Indoco Remediess Ltd.f the investigated drugs.
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The HPLC system consisted of Waters Alliance solvent manage-
ment system 2695, a photodiode array detector (DAD) 2998,
thermostatically controlled column apartment and an auto-sampler
with a 250 μL loop. The control of HPLC system and data pro-
cessing were performed using Empowers version 2 Software
(All Waters, Milford, MA, USA). pH measurements were carried
out using Metrohm pH meter 744 (Metrohm Ltd. CH 9101,
Herisau, Switzerland). Degradation experiments in acid, alkaline
and neutral conditions were performed using a water bath (model
DB28120-26, Thermolyne, Iowa, USA). Dry air oven (Postfach
102, GmbH Binder, Tuttlingen, Germany) was used to study the
effect of dry heat.
2.3. Chromatographic conditions
The chromatographic separations were achieved on X-Bridge
(Waters, Milford, MA, USA) C18 column (150 mm 4.6 mm
i.d.), 3.5 mm particle size, 135 Å pore diameter and 185 m2/g
surface area. Two mobile phases were used: the ﬁrst for RZ–MR
mixture consisted of acetonitrile: 0.025 M KH2PO4 solution: TEA
(30:69:1, v/v) adjusted to pH 7.0 using orthophosphoric acid
solution; the second for RZ–IO mixture consisted of acetonitrile:
0.025 M KH2PO4 solution: TEA (25:74:1, v/v) adjusted to pH
9.25. The mobile phases were ﬁltered through 0.45 mm membrane
ﬁlter and degassed ultrasonically before use. The elution was
performed in an isocratic mode with a ﬂow rate at 2 mL/min and
column temperature maintained at 40 1C. The detector was set at
wavelength range of 200–400 nm with sampling rate at 10 points/s
and spectral resolution 1.2 nm. The HPLC chromatograms were
recorded at 283 nm. The UV spectra (spectrograms) were collected
at different time intervals across the peak elution time and were
smoothed at level 5 and their derivative spectra at level 9. The
purity parameters included 100% active peak region and auto-
threshold with non-purity pass level. DAD library search was set at
threshold degree 10.0 and level 3 in depth. A search threshold
criterion of the noise due to instrument and solvent was at angle
1.0. The retention time pre-search was at 75% (tr window %).
The wavelength pre-search (window %) was at 71 nm.
2.4. Generation of stress samples for development of stability-
indicating methods
Forced degradation of each of drug substances and their binary
mixtures (i.e., RZ–MR or RZ–IO) was carried out under thermo-
lytic, photolytic, acid/base hydrolytic and oxidative stress
conditions.
Thermal and photo-degradation of drug substances and drug
mixtures was carried out in solid state. For thermal stress, samples
of drug substances and drug mixture were placed in a temperature-
controlled oven at 60 1C for 8 h. For photolytic stress, samples of
drug substances and drug product, in solid state, were irradiated
with UV radiation having peak intensities at 254 and 366 nm
for 8 h.
For hydrolytic and oxidative degradation, solutions were pre-
pared by dissolving drug substance or drug mixture in acetonitrile:
water (1:1 as diluent) and later diluted with 0.01 M hydrochloric
acid, 0.5 M sodium hydroxide and 0.3% hydrogen peroxide
solution to achieve a concentration of 1000 mg/mL for each of
RZ and MR or RZ and IO mixtures, respectively. During the initialforced degradation experiments, it was observed that acid hydro-
lysis was a fast reaction for RZ and almost complete degradation
occurred within 1 h at ambient temperature when 0.1 M hydro-
chloric acid was used. Thus, in later experiment, acid hydrolysis of
drug substance and drug mixtures in solution state was conducted
using 0.01 M hydrochloric acid solutions at ambient temperature
for 1 h, neutralized using 0.05 M sodium hydroxide and kept in a
cool dark place immediately. Alkaline and neutral hydrolysis was
conducted at 60 1C for 8 h in water. For oxidative stress, sample
solutions of drug substance and drug mixtures in 0.3% hydrogen
peroxide were kept in dark at ambient temperature for 24 h. The
sample solutions for acid/alkaline hydrolysis and oxidation were
diluted with mobile phase to get solutions containing 200 mg/mL for
RZ and MR or RZ and IO mixtures, respectively. All of the above-
diluted solutions were ﬁltered through 0.45 mm PVDF membrane
ﬁlter and then 10 mL aliquots were injected into HPLC system.
2.5. Optimization of the stability-indicating HPLC methods
Studies were carried out ﬁrst on samples of different stress
conditions for each drug individually and later on resolution of
drug and degradation mixtures were studied in a mixture of
solutions in which decomposition was observed. Finally, resolu-
tion of both intact drugs and their corresponding stress-formed
degradation products mixture was achieved.
2.6. Preparation of standards solutions for RZ–MR and RZ–IO
mixtures
Stock standard solutions were prepared by dissolving each of
drugs in acetonitrile: water mixture as diluents to achieve
concentration of 1000 mg/mL. Aliquots were diluted with mobile
phase to achieve the concentrations 200 and 150 mg/mL for RZ
and MR or 20 and 150 mg/mL for RZ and IO.
2.7. Analysis of pharmaceutical preparations
Twenty capsules for Veloz-Ms or Zorites capsules were
weighed; the average weight of each capsule was calculated. An
amount of powdered mass equivalent to 40 mg of RZ and 30 mg
of MR (for Veloz-Ms) and 4 mg of RZ and 30 mg of IO (for
Zorites) was weighed and transferred to 100 mL volumetric
ﬂasks. The drugs from powder were extracted and completed to
volume with diluent. To ensure complete extraction of drugs it
should be sonicated for 10 min. The extract was centrifuged at
3000 rpm and the supernatant solution was ﬁltered through
0.45 mm PVDF membrane ﬁlter. Appropriate aliquots from sample
stock solution were suitably diluted with mobile phase to obtain
solutions containing 200 and 150 mg/mL for RZ and MR and 20
and 150 mg/mL for RZ and IO. A 10 mL was injected into HPLC
concurrently with the appropriate standard mixture solution for
each of binary mixtures.
2.8. Validation procedure
The proposed HPLC–DAD method was validated according
to ICH guidelines [25] and USP analytical method validation
parameters [27] concerning system suitability test, speciﬁcity,
linearity, accuracy, precision, limit of detection (LOD), limit of
quantitation (LOQ) and robustness.
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The system suitability test parameters of the optimized method
were calculated using Empowers 2 Software.2.8.2. Speciﬁcity
The speciﬁcity of the proposed methods towards the investigated
compounds was illustrated through study of resolution and
capacity factors of the intact drugs, i.e., RZ and MR or RZ and
IO, by analyzing the peaks with respect to each other in binary
mixture and to the nearest degradation peaks, respectively. In
addition, the speciﬁcity was established throughout the study of
the purity and matching plots using Empowers2 Software. The
spectral homogeneity and purity of the peaks due to the eluted RZ,
MR and IO in their binary mixtures were also checked using the
methods of relative absorption spectra (RA) and log A versus the
wavelength plots. The absorption spectra (spectrograms) collected
at different time intervals across the elution of the peaks of RZ,
MR and IO were used to construct their RA spectra and log A
versus λ plots [28,29].2.8.3. Linearity
The linearity of the detector response with the concentrations of the
investigated drugs was evaluated. Stock standard solutions were
prepared at strengths 2 mg/mL of RZ, 1.5 mg/mL of MR and 15 mg/
mL of IO. Dilution with the mobile phase was carried out to obtain
two series of standard mixture solutions containing concentrationsTable 1 System suitability results of the proposed HPLC methods f
Solution Composition System suitability
Capacity
factor(K′)
Res
(Rs)
RZ–MR standard mixture RZ 3.955 –
MR 11.22 21.3
RZ–IO standard mixture RZ 2.577 –
IO 6.272 15.3
Stress-degraded RZ–MR matrix plus
RZ–MR standard
Peak I 3.399 –
RZ 3.977 3.28
Peak II 4.889 4.54
Peak III 7.994 –
MR 11.25 8.75
Peak IV 15.03 8.01
Stress-degraded RZ–IOmatrix plus
RZ–IO standard
Peak I 1.844 –
RZ 2.209 2.66
Peak II 3.674 12.2
Peak III 4.332 –
IO 5.617 4.50
Peak IV 7.549 4.50
Acceptance criteria 0.54Xo15 42
aα and Rs are the selectivity factor and the resolution, respectively, betw
bRSD % for three determinations.
cPeak area.ranging from 50 to 400 mg/mL, 25 to 300 mg/mL of RZ and MR, 5 to
40 mg/mL, 50 to 300 mg/mL of RZ and IO, respectively. The
solutions were injected in triplicate into the HPLC system. Peak
areas were plotted versus the corresponding concentration to obtain
calibration graphs. Regression data analysis was performed using
least squares linear regression statistical analysis.2.8.4. Accuracy
The accuracy of the methods was evaluated by spiking a mixture
of stress-degraded samples with RZ–MR and RZ–IO binary
mixtures at three different concentrations. The percentage recov-
eries of RZ and MR, and RA and IO were calculated from the
difference between the peak areas of fortiﬁed and unfortiﬁed
solutions. Also recovery studies were carried out by applying the
standard addition method to pharmaceutical preparations i.e.,
Veloz-Ms and Zorites capsules.2.8.5. Precision
For determination of repeatability, ten samples solutions were
prepared at 100% level of the analytical method concentration
and kept in a cool dark place. The results were expressed as
RSD% for the ten determinations. The intra-day precision studies
were performed by analysis of three different concentrations at
80%, 100% and 120% of the analytical concentration of the drug
in triplicate (n¼3) on the same day. The inter-day precisionor separation of RZ in two binary mixtures.
parameters
olution
a
Selectivity
factor (α)a
Tailing
factor
Column
efﬁciency
RSD%b
tr PA
c
– 1.01 8955 0.24 0.54
2.838 0.98 11,567 0.27 0.66
– 1.09 7048 0.77 0.62
2.375 1.07 8576 0.33 0.58
1.145 1.30 8253 0.33 0.77
1.173 1.01 11,398 0.27 0.83
1.227 0.96 12,146 0.44 1.22
1.320 0.97 13,410 0.55 1.44
1.407 0.95 12,443 0.31 0.65
1.336 0.96 14,609 0.88 1.66
1.312 1.24 5788 0.55 0.96
1.198 1.03 6423 0.44 0.66
1.663 1.33 55,147 0.39 1.02
1.179 1.47 6502 1.08 1.11
1.297 1.04 7422 0.64 0.82
1.344 1.17 3819 0.72 0.66
41 o2.0 42000 o2.0 o2.0
een two consecutive peaks in the elution order.
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days.2.8.6. LOD and LOQ
ICH guideline Q2 (R1) [25] describes several approaches to deter-
mine the detection and quantitation limits. These include visual
evaluation, signal-to-noise ratio and the use of standard devia-
tion of the response and the slope of the calibration curve.
In the present study, the LOD and LOQ were based on the
third approach and calculated according to the 3.3s/s and 10s/s
criteria, respectively; where s is the standard deviation of theFig. 2 Chromatogram of a mixture of stress degradation products of
index plots.intercept values and s is the slope of the corresponding calibration
curve.
2.8.7. Robustness
Robustness of an analytical procedure is a measure of its capacity to
remain unaffected by small, but deliberate, variation in method
parameters such as slight change of % organic modiﬁer and pH of
the mobile phase. Thus these values were selected one below and one
above the optimized values used in the chromatographic conditions.
Robustness of the proposed method was evaluated in terms of system
suitability parameters of drug peak in a mixture of stress-degraded
samples towards the small-intended afore-mentioned variations.RZ–MR in their binary mixture and their corresponding spectrum
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3.1. Development and optimization of the HPLC methods
During the optimization of the separation method, three
columns (Kromasil C18: 5 mm, 250 mm 4.6 mm; Symmetry
C18: 5 mm, 150 mm 4.6 mm; and X-Bridge C18: 3.5 mm,
150 mm 4.6 mm) and the mobile phase composed of acetoni-
trile and 0.025 M phosphate buffer solution adjusted to ﬁve
different pH values (5–7.5) with and without TEA were tested.
Of the stationary phases experienced, X-Bridge column wasFig. 3 Chromatogram of a mixture of stress degradation products of RZ–Ichosen and the most suitable separation factors were obtained as
it is suitable for retention of basic compounds at high pH and in
high percentage aqueous mobile phases. After trying several
mobile phases containing acetonitrile with various buffer
proportions, the mobile phase consisting of acetonitrile:
0.025 M KH2PO4 buffer solution: TEA (1%) was proved to
be useful for better resolution and peak symmetry. To optimize
this mobile phase, proportions of acetonitrile and 0.025 M
KH2PO4 buffer were systematically changed from 50:50 whilst
percentage of TEA (1% pH 6.0) remained unchanged. Higher
acetonitrile ratio resulted in shorter retention times of allO in their binary mixture and their corresponding spectrum index plots.
H. M. El-Fatatry et al.264analytes whereas all three analytes tended to elute later with
increasing ratio of buffer solution. For further optimization
acetonitrile, 0.025 M KH2PO4 buffer solution and TEA were
mixed at a ratio of 30:69:1 (v/v/v) adjusted to different pH values
varied in the range of 5.0–7.5. As a result of pH screening, the
optimum mobile phase was chosen as acetonitrile: 0.025 M
KH2PO4 buffer solution: TEA (at ratio 30:69:1) adjusted to pH
7.0. The ﬂow rate used was set to 2.0 mL/min at column
temperature 40 1C. Best chromatographic results were obtained in
terms of peak symmetry, resolution, selectivity and analysis time for
separation of RZ and MR in the presence of their corresponding
generated stress degradation products. Further modiﬁcations
required for separation of RZ–IO mixture to elute IO after RZ to
improve the resolution between IO and degradation products that
originated from its acid degradation and to avoid the co-elution of
IO with cluster of peaks due to RZ stress-generated degradation
products. The mobile phase composed of acetonitrile: 0.025 M
KH2PO4 buffer solution: TEA at a ratio of 25:74:1 adjusted to pH
9.25 was chosen to obtain best results in term of resolution and peak
symmetry for separation of RZ and IO in the presence of their
corresponding stress-generated degradation products. The chroma-
tograms were recorded at 283 nm. Separation parameters are
summarized in Table 1. Figs. 2 and 3 show the chromatograms
and spectrum index plots of RZ–MR and RZ–IO in a mixture of
their ICH-generated degradations from all their corresponding stress
conditions, respectively.Table 2 Summary of forced degradation studies for two binary mix
Composition Stress condition
RZ–MR binary mixture I
RZ Control (no degradation)
Acid hydrolysis (0.5 M HCl at 60 1C)
Acid hydrolysis (0.1 M HCl at room tem
Acid hydrolysis 0.01 M HCl at room te
Basic hydrolysis (0.5 M NaOH at 60 1C
Oxidation (0.3% H2O2 in dark for 24 h)
Thermal decomposition (at 80 1C for 8
Photodecomposition under UV for 8 h
MR Control (no degradation)
Acid hydrolysis (0.5 M HCl at 80 1C fo
Basic hydrolysis (0.5 M NaOH at 80 1C
Oxidation(0.3% H2O2 in dark for 24 h)
Thermal decomposition (at 80 1C for 8
Photodecomposition under UV for 8 h
RZ–IO binary mixture II
RZ Control (no degradation)
Acid hydrolysis (0.5 M HCl at 60 1C)
Acid hydrolysis (0.1 M HCl at room tem
Acid hydrolysis 0.01 M HCl at room te
Basic hydrolysis (0.5 M NaOH at 60 1C
Oxidation (0.3% H2O2)
Thermal decomposition (at 80 1C for 8
Photodecomposition under direct daylig
IO Control (no degradation)
Acid hydrolysis (0.5 M HCl at 80 1C fo
Basic hydrolysis (0.5 M NaOH at 80 1C
Oxidation(0.3% H2O2 in dark for 24 h)
Thermal decomposition (at 80 1C for 8
Photodecomposition under direct UV fo3.2. Stability studies
The results in Table 2 indicated that RZ underwent extensive
degradation in acid, H2O2 and photolysis. Moderate degradation
occurred in thermal and neutral conditions. RZ was relatively
stable in alkaline medium at room temperature and showed
moderate degradation upon reﬂuxed with 0.5 M NaOH at 60 1C.
Meanwhile MR underwent moderate degradation in all stress
conditions. Like MR, IO showed similar degradation pattern but to
more extent in acid/base hydrolysis. Fig. 4 shows the chromato-
grams of forced degraded samples for both RZ–MR and RZ–IO
mixtures in different stress conditions.
3.3. Validation of the developed stability-indicating methods
3.3.1. System suitability test
The capacity factors (K′) of the investigated drugs were 3oK′
o12 and the resolution between their peaks and the closest peak
was higher than 2.5. The plate count was more than 5000 and their
symmetry factors were in between 0.94 and 1.03. The results are
summarized in Table 1.
3.3.2. Stability/speciﬁcity
Speciﬁcity can be described as the capability of the method to
accurately measure the response of the two analyzed compoundstures (RZ–MR and RZ–IO).
Recovery of intact drug (%)
99.60
2.66
perature for 1 h) 21.78
mperature for 1 h) 52.99
for 8 h) 89.56
72.98
h) 88.56
76.99
99.71
r 8 h) 84.99
for 8 h) 96.98
67.67
h) 97.70
68.99
99.17
2.78
perature for 1 h) 22.54
mperature for 1 h) 44.77
for 8 h) 86.81
70.11
h ) 89.88
ht 84.99
99.44
r 8 h) 72.77
for 8 h) 90.99
85.99
h) 96.66
r 8 h 90.77
Fig. 4 Chromatograms of mixture of acid (A), alkaline (B), oxidation (C), neutral (D) and photo induced (E) degradation of RZ and MR in their
mixture (I) and RZ and IO in their mixture (II).
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originating from sample matrix. High percentage recovery
observed with assay samples of pharmaceutical dosage forms,
including standard addition experiments, indicates that the pro-
posed methods were not affected by interferences from mixture of
stress-degraded samples and excipients used in formulations. The
resolution factor for the drug peaks in the mixture of degradation
solutions was 43 from the nearest resolving degradation peaks as
in Table 1. DAD also supported the speciﬁcity of the method and
provided evidence for the homogeneity of the peaks of analytes as
the purity angles were always found much less than the threshold
limit in all stressed samples. In addition, the observation that the
wavelengths of derivative optima (ﬁrst, second, third and fourth)
of the spectrograms of the separated peaks obtained by chromato-
graphy of the test solutions were identical to those of correspond-
ing standard was considered as evidence conﬁrming the identity ofFig. 5 The spectrograms (A), their log A (B) and their relative absorption
ICH-stress formed degradation (I) and RZ–IO peaks in their ICH-stress fo
Table 3 Analytical data and regression characteristics of rabeprazol
Parameters RZa MRa
Calibration range (mg/mL) 50–400 50–30
Detection limit (mg/mL) 0.415 0.442
Quantitation limit (mg/mL) 1.257 1.339
Regression equation (Y)c
Slope (b) 12,065.8 7950
SD of the slope (Sb) 77.94 64.09
RSD of the slope (%) 0.646 0.806
Conﬁdence limit of the sloped 11849.4–12282.2 7772
Intercept (a) 5613.13 1633
SD of the intercept (Sa) 1515.74 1063
Conﬁdence limit of the intercept 3035.5–4553.2 326
Correlation coefﬁcient (r) 0.9999 0.999
aUsing the HPLC method for RZ–MR mixture.
bUsing the HPLC method for RZ–IO mixture.
cY¼aþbC; where C is the concentration in mg/mL and Y is the peak are
d95% conﬁdence limit.the investigated compounds [28,29]. The derivative spectra were
super-imposable whenever overlaid, showing that there were no
other co-eluting peaks. Furthermore, the spectral homogeneity and
purity of the peaks were conﬁrmed using RA spectra and log A
versus the wavelength plots [28,29] constructed from the data
collected from the spectrograms of each peak. The superimpose of
the relative absorption spectra and the traces of log A versus the
wavelengths plots with those of corresponding standard for each
peak proved the absence of interference as shown in Fig. 5.3.3.3. Linearity
A linear simple regression by the least squares method was
applied. The correlation coefﬁciencies (r) were found to be greater
than 0.999 in all instances. Table 3 shows calibration character-
istics for RZ–MR and RZ–IO binary mixtures.(RA) (C) spectra versus the wavelength plots of RZ–MR peaks in their
rmed degradation (II).
e sodium, mosapride citrate and itopride hydrochloride.
RZb IOb
0 5–40 50–300
0.357 0.204
1.071 0.612
.2 13397.6 5503.4
74.38 25.58
0.555 0.465
.2–8127.1 13191.1–13604.1 4852.1–6154.7
1.85 1654.47 25762.98
.84 1449.37 340.18
62.1–17127.5 3308–1736.7 24474.8–27051.2
9 0.9999 0.9996
a.
Table 4 Recovery data for rabeprazole, mosapride and itopride in a mixture of their ICH-stress formed degradation products.
Matrix % Targeting
concentration
Added (mg/mL) Meanb % recovery (RSD% )
RZ MR IO RZ MR IO
Mixture of stress-degraded samples for RZ–MR
mixture
80 160a 120 (–)c 100.52 (1.28) 101.34 (0.82) (–)
100 200 150 (–) 101.39 (0.85) 100.77 (0.98) (–)
120 240 180 (–) 102.21 (0.89) 99.88 (1.06) (–)
Mixture of stress-degraded samples for RZ–IO
mixture
80 16 (–) 120 99.87 (0.94) (–) 99.08
(1.14)
100 20 (–) 150 100.90 (1.11) (–) 102.95
(1.53)
120 24 (–) 180 99.66 (0.92) (–) 99.58
(1.15)
a% of targeting concentration of intact drug presented as % of the method concentration.
bMean of three determinations.
c(–) means it is not a component of formulation.
Table 5 Determination of intact drugs in their pharmaceutical preperations.
Pharmaceutical preparation Batch identity symbola Mean % found (RSD% )b
RZ MR IO
RZ–MR capsule BT I 98.28 (0.88) 99.51 (0.78) (–)c
BT II 99.55 (1.62) 100.10 (1.29) (–)
BT III 97.81 (0.96) 102.29 (1.59) (–)
RZ–IO capsule BT I 98.21 (0.32) (–) 99.51 (1.08)
BT II 99.04 (0.48) (–) 99.94 (0.99)
BT III 99.89 (0.69) (–) 101.88 (1.05)
aBT I, II, III refers to the three batches tested.
bMean and RSD % for three determinations.
c(–) means it is not a component of formulation.
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The mean percentage recoveries obtained after six repeated
experiments were found between 99.50% and 103.0%. The RSD
values were less than1.65% (Table 4) indicating that the results are
accurate and precise and there is no interference from the common
excipients used in the pharmaceutical dosage forms.3.3.5. Precision
The developed methods were found to be precise as the RSD
values for repeatability and intermediate precision studies were
less than 2.0%.3.3.6. LOD and LOQ
The LOD and LOQ values of the developed method are presented
in Table 3.3.3.7. Robustness
The results of robustness studies proved that slight but deliberate
changes of the optimized chromatographic parameters would
affect neither the retention of the compounds, as indicated by
their capacity factors (k′), nor the resolution between any two
consecutive peaks indicating that the proposed methods are robust.3.4. Application to pharmaceutical preparations
The proposed validated stability-indicating HPLC methods were
applied to the determination of RZ in two binary mixtures, Veloz-
Ms (RZ and MR) and Zorites (RZ and IO) capsules. Table 5
shows the mean percentage drugs found and the RSD% values
indicating that the proposed validated stability-indicating HPLC
methods could be adopted for the selective determination of the
investigated drugs in their pharmaceutical preparations without
interference from either their corresponding degradation products
formed under ICH-recommended stress conditions and co-
Fig. 6 (A) Representative chromatogram of test RZ–MR capsules
solution labeled to contain 200 mg/mL of RZ and 150 mg/mL of MR,
(B) Representative chromatogram of test RZ–IO capsules solution
labeled to contain 20 mg/mL of RZ and 150 mg/mL of IO.
H. M. El-Fatatry et al.268formulated adjuvants. Representative chromatograms are illu-
strated in Fig. 6.4. Conclusion
Based on the peak purity results, obtained from the analysis of
forced degraded samples using described methods, it can be
concluded that there is no other co-eluting peak with the main
peaks and the methods are speciﬁc for the estimation of RZ in two
binary mixtures containing MR and IO in the presence of their
corresponding stress-generated degradation products. The methods
have linear response in stated range and are accurate and precise.
Though no attempt was made to identify the degradation products,
described methods can be used as stability-indicating methods for
assay of RZ in its two combination drug products. It can be
concluded that the proposed methods have a great promise as rapid
analytical tools for the simultaneous estimation of RZ–MR and
RZ–IO in their combined pharmaceutical formulations, especially
for quality control laboratories.References
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